logo

Acelrx Pharmaceuticals Inc. (ACRX)



Trade ACRX now with
  Date
  Headline
5/26/2021 9:49:32 AM AcelRx Announces Presentation On Use Of DSUVIA For Plastic Surgery Procedures Selected For "Best Papers" Session
5/20/2021 8:50:50 AM AcelRx Announces Investigator-initiated Study To Be Conducted At Tampa General Hospital To Evaluate DSUVIA
5/17/2021 4:05:58 PM AcelRx Pharma Q1 Loss/share $0.08 Vs. Loss $0.20 Year Ago
5/13/2021 9:49:14 AM AcelRx : Study Of DSUVIA Showing Reduction In Postoperative Opioids And Better OBAS Scores Compared To Control Group
3/31/2021 8:32:24 AM AcelRx Appoints Marina Bozilenko As An Independent Member Of Board
3/25/2021 8:42:22 AM AcelRx Announces Publication Of Pooled Analysis Of Phase 3 Data On Use Of DSUVIA For Acute Pain Management
3/15/2021 5:21:25 PM AcelRx Pharmaceuticals Q4 Loss/share $0.10 Vs. Loss $0.18 Year Ago
1/20/2021 9:03:42 AM AcelRx Prices $27.5 Mln Public Offering Of Common Stock
3/3/2017 6:51:55 AM RBC Capital Markets Is Lowering AcelRx Pharmaceuticals Inc. (ACRX) 2018 Rev. Estimate To 36.3 M From 39.3 M
3/3/2017 6:51:43 AM RBC Capital Markets Is Lowering AcelRx Pharmaceuticals Inc. (ACRX) 2017 Rev. Estimate To 13.4 M From 15.0 M
3/3/2017 6:51:32 AM RBC Capital Markets Is Lowering AcelRx Pharmaceuticals Inc. (ACRX) Q4 17 Rev. Estimate To 2.5 M From 4.2 M
3/3/2017 6:51:05 AM RBC Capital Markets Is Cutting AcelRx Pharmaceuticals Inc. (ACRX) 2018 Estimate To -0.71 From -0.70
3/3/2017 6:50:50 AM RBC Capital Markets Is Increasing AcelRx Pharmaceuticals Inc. (ACRX) 2017 Estimate To -0.99 From -1.03
3/3/2017 6:50:28 AM RBC Capital Markets Is Raising AcelRx Pharmaceuticals Inc. (ACRX) Q3 17 Estimate To -0.26 From -0.28